Premium
Second donation of granulocyte–colony‐stimulating factor–mobilized peripheral blood progenitor cells: risk factors associated with a low yield of CD34+ cells
Author(s) -
Platzbecker Uwe,
Bornhäuser Martin,
Zimmer Kristin,
Lerche Linda,
Rutt Claudia,
Ehninger Gerhard,
Hölig Kristina
Publication year - 2005
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2005.04107.x
Subject(s) - granulocyte colony stimulating factor , medicine , progenitor cell , cd34 , mobilization , transplantation , granulocyte , filgrastim , urology , immunology , surgery , gastroenterology , stem cell , chemotherapy , biology , history , archaeology , genetics
BACKGROUND: There are still limited data on the efficacy and safety of repeated donations of granulocyte–colony‐stimulating factor (G–CSF)‐mobilized peripheral blood progenitor cells (PBPCs) for allogeneic transplantation. STUDY DESIGN AND METHODS: Sixty‐seven healthy donors undergoing two consecutive mobilizations of PBPCs within a median interval of 5 months (range, 0.1‐47 months) were investigated. For both first mobilization (FM) and second mobilization (SM), G–CSF (lenograstim) at 7.5 µg per kg per day was administered. RESULTS: The nonhematologic side effects were comparable between both mobilizations. A significantly lower yield of CD34+ cells × 10 6 per kg of donor weight was obtained on Day 5 of SM in female (n = 31; FM, 5.0; SM, 3.23; p = 0.008) but not in male (n = 36; FM, 5.96; SM, 5.36; p = 0.24) donors. Multivariate analysis identified a lower CD34+ blood concentration on Day 5 of FM (p < 0.001) as well as female sex (p = 0.015) as independent risk factors for a lower yield of progenitor cells, whereas donor age and body mass index, interval between donations, and schedule of G–CSF application showed no significant impact. CONCLUSION: The identified risk factors allow the estimation of the efficacy of a SM in an individual donor before G–CSF administration, thus avoiding distress to both the donor and the recipient.